Interventional device developer Boston Scientific of Natick, MA, has received clearance from the U.S. Food and Drug Administration (FDA) for its Taxus Liberté Long paclitaxel-eluting coronary stent system, a drug-eluting stent designed for long lesions.
The device is 38 mm long, helping users reduce the number of stents in more complex cases and simplifying procedures for patients with long lesions, the company said.
Boston Scientific plans to launch the stent next month.
Related Reading
FDA clears Boston Scientific catheter, May 28, 2009
Boston Scientific debuts coronary imaging catheter, March 20, 2009
Boston Scientific submits Taxus PMA data, February 5, 2009
Boston Scientific to bring Taxus Liberté to Japan, January 29, 2009
Boston Scientific, Medtronic bury the hatchet, January 28, 2009
Copyright © 2009 AuntMinnie.com
